1 / 7

Roles of Protease Inhibitors for HIV-infected Children

Roles of Protease Inhibitors for HIV-infected Children. Jintanat Ananworanich. National Security Office Database. As of July 20, 2013 N of Thai children on ART = 5543 N of children on LPV/r = 1548 N of children on ATV/r = 32

dyanne
Télécharger la présentation

Roles of Protease Inhibitors for HIV-infected Children

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Roles of Protease Inhibitors for HIV-infected Children Jintanat Ananworanich

  2. National Security Office Database • As of July 20, 2013 • N of Thai children on ART = 5543 • N of children on LPV/r = 1548 • N of children on ATV/r = 32 • Also some children on double-boosted PI (LPV/r + SQV or IDV) and on IDV/r • A few on unboosted IDV or treatment dose of RTV (not recommended) Data from Mr. ArtitPusamang and Dr. Sorakij Bhakeecheep

  3. Use of PI in Treating Pediatric HIV First-line Failure ~ 30% at 4 yrs1 N=1600 in NHSO Second-line Failure ~ 30% at 1 yr2 N=480 Third-line/salvage Failure ~ 20% at 7 mo3 N=96 1Puthanakit T, PIDJ 2007; 2Puthanakit T, AIDS Res Ther 2012; 3Ananworanich J, 2012 IAS

  4. HIVNAT 113 patient population(Failed NRTI/NNRTI/PI) HIV-NAT, Siriraj, Bamrasnaradura, Srinagarind, Nakornping, Chiang Rai, Prapokklao, Surin

  5. Data in Adults

  6. Virologic Responses of Commonly Used Third ARV for the Initial HAART Data from various clinical trials of treatment-naïve patients % of patients with VL<50 at 96 weeks except STARTMRK at 48 weeks (ITT) *EFV, ATV/r, DRV/r superiority to LPV/r ACTG5142 STARTMRK CASTLE ARTEMIS ACTG 5142, CASTLE, ARTEMIS = 96 weeks, STARTMRK=48 weeks results All combined with 2 NRTIs From the slide collection of Prof. Kiat Ruxrungtham

  7. Virologic Responses in Treatment-experienced Trials (most data at 48 wks) Wk 96 Wk 144 Active 50% 37% <33% 75% 17% OBR≥2 ETR+DRV/rRAL DRV/r MVC DRV/r DRV/r RAL+ETR+DRV/r ENF

More Related